The rationale behind developing c-Met kinase inhibitors for the treatment of cancer is based on multiple lines of preclinical evidence showing that aberrant activation of the c-Met/HGF signaling pathway plays a pivotal role in cancer progression and metastasis by promoting cell proliferation, survival, and motility [32]. The gene discussed is MET; the disease is cancer.